



Literaturverzeichnis zum Beitrag „Strategien von Legionellen zur Besiedlung und Zerstörung der Lunge“ (*Epidemiologisches Bulletin* 2007; 50: 473–475)

1. Aragon V, Kurtz S, Flieger A, Neumeister B, and Cianciotto NP: Secreted enzymatic activities of wild-type and pilD-deficient *Legionella pneumophila*. *Infect Immun* 2000; 68: 1855–1863
2. Banerji S, Aurass P, and Flieger A: The manifold phospholipases A of *Legionella pneumophila* – identification, export, regulation, and their link to bacterial virulence. *Int J Med Microbiol* 2008
3. Banerji S, Bewersdorff M, Hermes B, Cianciotto NP, and Flieger A: Characterization of the major secreted zinc metalloprotease-dependent glycerophospholipid:cholesterol acyltransferase, PlaC, of *Legionella pneumophila*. *Infect Immun* 2005; 73: 2899–2909
4. Banerji S, and Flieger A: Patatin-like proteins: a new family of lipolytic enzymes present in bacteria? *Microbiology* 2004; 150: 522–525
5. Brieland JK, Fantone JC, Remick DG, LeGendre M, McClain M, and Engleberg NC: The role of *Legionella pneumophila*-infected *Hartmannella vermiformis* as an infectious particle in a murine model of Legionnaire's disease. *Infect Immun* 1997; 65: 5330–5333
6. Cianciotto NP: Pathogenicity of *Legionella pneumophila*. *Int J Med Microbiol* 2001; 291: 331–343
7. DebRoy S, Dao J, Soderberg M, Rossier O, and Cianciotto NP: *Legionella pneumophila* type II secretome reveals unique exoproteins and a chitinase that promotes bacterial persistence in the lung. *Proc Natl Acad Sci U. S. A* 2006; 103: 19146–19151
8. Dennis EA: The growing phospholipase A2 superfamily of signal transduction enzymes. *Trends Biochem Sci* 1997; 22: 1–2
9. Edelstein PH: Legionnaires' disease. *Clin Infect Dis* 1993; 16: 741–747
10. Fields BS: The molecular ecology of legionellae. *Trends Microbiol* 1996; 4: 286–290
11. Flieger A, Gong S, Faigle M, Deeg M, Bartmann P, and Neumeister B: Novel phospholipase A activity secreted by *Legionella* species. *J Bacteriol* 2000; 182: 1321–1327
12. Flieger A, Gong S, Faigle M, Stevanovic S, Cianciotto NP, and Neumeister B: Novel lysophospholipase A secreted by *Legionella pneumophila*. *J Bacteriol* 2001; 183: 2121–2124
13. Flieger A, Gongab S, Faigle M, Mayer HA, Kehrer U, Mussotter J, Bartmann P, and Neumeister B: Phospholipase A secreted by *Legionella pneumophila* destroys alveolar surfactant phospholipids. *FEMS Microbiol Lett* 2000; 188: 129–133
14. Flieger A, Neumeister B, and Cianciotto NP: Characterization of the gene encoding the major secreted lysophospholipase A of *Legionella pneumophila* and its role in detoxification of lysophosphatidylcholine. *Infect Immun* 2002; 70: 6094–6106
15. Flieger A, Ryzdzewski K, Banerji S, Broich M, and Heuner K: Cloning and characterization of the gene encoding the major cell-associated phospholipase A of *Legionella pneumophila*, plaB, exhibiting hemolytic activity. *Infect Immun* 2004; 72: 2648–2658
16. Hales LM and Shuman HA: *Legionella pneumophila* contains a type II general secretion pathway required for growth in amoebae as well as for secretion of the Msp protease. *Infect Immun* 1999; 67: 3662–3666
17. Holm BA, Keicher L, Liu MY, Sokolowski J, and Enhorning G: Inhibition of pulmonary surfactant function by phospholipases. *J Appl Physiol* 1991; 71: 317–321
18. Horwitz MA: Formation of a novel phagosome by the Legionnaires' disease bacterium (*Legionella pneumophila*) in human monocytes. *J Exp Med* 1983; 158: 1319–1331
19. Horwitz MA: The Legionnaires' disease bacterium (*Legionella pneumophila*) inhibits phagosome-lysosome fusion in human monocytes. *J Exp Med* 1983; 158: 2108–2126
20. Kume N, Cybulsky MI, and Gimbrone, Jr MA: Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. *J Clin Invest* 1992; 90: 1138–1144
21. Lema G, Dryja D, Vargas I, and Enhorning G: *Pseudomonas aeruginosa* from patients with cystic fibrosis affects function of pulmonary surfactant. *Pediatr Res* 2000; 47: 121–126
22. Liles MR, Edelstein PH, and Cianciotto NP: The prepilin peptidase is required for protein secretion by and the virulence of the intracellular pathogen *Legionella pneumophila*. *Mol Microbiol* 1999; 31: 959–970
23. Masamune A, Sakai Y, Satoh A, Fujita M, Yoshida M, and Shimosegawa T: Lysophosphatidylcholine induces apoptosis in AR42J cells. *Pancreas* 2001; 22: 75–83

24. Molofsky AB and Swanson MS: Differentiate to thrive: lessons from the *Legionella pneumophila* life cycle. *Mol Microbiol* 2004; 53: 29–40
25. Niewoehner DE, Rice K, Sinha AA, and Wangenstein D: Injurious effects of lysophosphatidylcholine on barrier properties of alveolar epithelium. *J Appl Physiol* 1987; 63: 1979–1986
26. Ninio S and Roy CR: Effector proteins translocated by *Legionella pneumophila*: strength in numbers. *Trends Microbiol* 2007; 15: 372–380
27. Pedro-Botet ML, Sabria-Leal M, Sopena N, Manterola JM, Morera J, Blavia R, Padilla E, Matas L, and Gimeno JM: Role of immunosuppression in the evolution of Legionnaires' disease. *Clin Infect Dis* 1998; 26: 14–19
28. Plotkowski MC and Meirelles MN: Concomitant endosome-phagosome fusion and lysis of endosomal membranes account for *Pseudomonas aeruginosa* survival in human endothelial cells. *J Submicrosc Cytol Pathol* 1997; 29: 229–237
29. Prokazova NV, Zvezdina ND, and Korotaeva AA: Effect of lysophosphatidylcholine on transmembrane signal transduction. *Biochemistry (Mosc.)* 1998; 63: 31–37
30. Robert Koch-Institut: Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2006; 2007
31. Rogers J and Keevil CW: Immunogold and fluorescein immunolabelling of *Legionella pneumophila* within an aquatic biofilm visualized by using episcopic differential interference contrast microscopy. *Appl Environ Microbiol* 1992; 58: 2326–2330
32. Rossier O and Cianciotto NP: Type II protein secretion is a subset of the PilD-dependent processes that facilitate intracellular infection by *Legionella pneumophila*. *Infect. Immun* 2001; 69: 2092–2098
33. Segal G, Purcell M, and Shuman HA: Host cell killing and bacterial conjugation require overlapping sets of genes within a 22-kb region of the *Legionella pneumophila* genome. *Proc Natl Acad Sci U. S. A* 1998; 95: 1669–1674
34. Shohdy N, Efe JA, Emr SD, and Shuman HA: Pathogen effector protein screening in yeast identifies *Legionella* factors that interfere with membrane trafficking. *Proc Natl Acad Sci U. S. A* 2005; 102: 4866–4871
35. Smith GA, Marquis H, Jones S, Johnston NC, Portnoy DA, and Goldfine H: The two distinct phospholipases C of *Listeria monocytogenes* have overlapping roles in escape from a vacuole and cell-to-cell spread. *Infect Immun* 1995; 63: 4231–4237
36. VanRheenen SM, Luo ZQ, O'Connor T, and Isberg RR: Members of a *Legionella pneumophila* family of proteins with ExoU (phospholipase A) active sites are translocated to target cells. *Infect Immun* 2006; 74: 3597–3606
37. Vogel JP, Andrews HL, Wong SK, and Isberg RR: Conjugative transfer by the virulence system of *Legionella pneumophila*. *Science* 1998; 279: 873–876
38. Weltzien HU: Cytolytic and membrane-perturbing properties of lysophosphatidylcholine. *Biochim Biophys Acta* 1979; 559: 259–287
39. Winn WC, Jr. and Myerowitz RL: The pathology of the *Legionella* pneumonias. A review of 74 cases and the literature. *Hum Pathol* 1981; 12: 401–422